Biocon Limited has commenced commercial sales of Yesafili (aflibercept-jbvf) in the United States, marking its entry into the high-value ophthalmology biosimilars market. The launch, effective August 3, 2026, targets a significant addressable market driven by an estimated 19.8 million Americans living with age-related macular degeneration (AMD). Yesafili serves as an interchangeable biosimilar to Regeneron's reference product, Eylea 2 mg, allowing pharmacy-level substitution in accordance with state laws. This move strengthens Biocon's presence in the US healthcare sector, leveraging its status as one of the first interchangeable biosimilars approved by the US Food and Drug Administration (FDA) in May 2024.

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the launch pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Rajesh U. Shanoy, Company Secretary and Compliance Officer, signed the intimation filed with the exchanges.

Management Outlook: Contracts, Market Share, and H2 Growth

In its latest concall update, Biocon's management expressed confidence in the commercial trajectory of Yesafili, anticipating a strong start supported by existing contracts already in place. The company projects a gradual increase in market share over time, with stronger growth expected in the second half. This outlook reflects management's strategy of leveraging established commercial relationships to drive early adoption of the biosimilar in the competitive US ophthalmology market.

Product Profile and Market Opportunity

Yesafili is indicated for the treatment of several serious eye conditions, including neovascular (wet) AMD, macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). As a vascular endothelial growth factor (VEGF) inhibitor, it addresses a critical unmet need in a market where aflibercept sales totaled approximately $5.89 billion in 2023. The product's approval was based on comprehensive analytical, nonclinical, and clinical data confirming its high similarity to Eylea 2 mg.

Shreehas Tambe, CEO & Managing Director of Biocon Ltd., stated that the launch represents a key step in expanding global availability of biosimilar Aflibercept 2 mg. He noted that the milestone builds on the company's earlier FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg, aiming to advance access to life-changing medicines for patients worldwide.

Clinical Validation and Safety

The approval for Yesafili relied on data from the Phase 3 INSIGHT Study, which compared the biosimilar against Eylea 2 mg in patients with Diabetic Macular Edema. The study demonstrated no clinically meaningful differences between the two products regarding pharmacokinetics, safety, efficacy, and immunogenicity. However, the product carries warnings for potential risks such as endophthalmitis, retinal detachments, and arterial thromboembolic events following intravitreal injections. Patients are advised to report any signs of infection or inflammation immediately.

Market Context

With nearly 20 million Americans affected by AMD and a reference product generating nearly $6 billion in recent annual sales, the economic potential for biosimilar penetration is substantial. The interchangeable designation is a critical differentiator, as it permits automatic substitution at pharmacies without additional physician intervention, potentially accelerating adoption rates compared to non-interchangeable biosimilars. Backed by existing contracts and a phased market share ramp-up strategy, Biocon's commercial approach for Yesafili aligns with its broader objective of providing affordable alternatives in high-unmet-need therapy areas across chronic and non-communicable diseases.

Biocon has flagged its GLP-1 product line as a significant growth driver, according to the company's latest conference call update. The development underscores the strategic importance of the GLP-1 segment within Biocon's broader product portfolio and business outlook.

GLP-1 Segment in Focus

The company's concall update drew attention to the GLP-1 product line as a continuing and major contributor to growth. This segment has been highlighted by management as a key area of focus, reflecting its relevance to Biocon's ongoing business strategy.

Key Takeaway

• The GLP-1 product line has been identified as a major growth factor for Biocon.
• The update was communicated through the company's official conference call.

The concall update reaffirms Biocon's continued emphasis on the GLP-1 segment as a cornerstone of its growth narrative. Stakeholders and investors will be closely watching further disclosures for detailed financial metrics and operational progress tied to this product line.